Sagimet Biosciences (NASDAQ:SGMT) used an investor discussion at Oppenheimer’s 36th Annual Healthcare Life Sciences ...

Please provide your email address to receive an email when new articles are posted on . AIM-MASH AI Assist is the first AI drug development tool to be qualified by the FDA. The tool is designed to ...

At the annual Liver Meeting sponsored by the American Association for the Study of Liver Diseases (AASLD), AASLD President Grace L. Su, MD, of the University of Michigan in Ann Arbor, highlighted ...

Please provide your email address to receive an email when new articles are posted on . PHOENIX — In this video, Mazen Noureddin, MD, MHSc, professor of medicine at Houston Methodist, highlights ...

MASLD/MASH represents a growing clinical and economic burden, with MASH conferring heightened risks of advanced fibrosis, cirrhosis, hepatocellular carcinoma, and liver-related mortality. Noninvasive ...